This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Feb 21;156(4):317-8.

doi: 10.7326/0003-4819-156-4-201202210-00014.

Hepatitis C: the end of the beginning and possibly the beginning of the end

Harvey J Alter, T Jake Liang

PMID: 22351718
PMCID: PMC3480337
DOI: 10.7326/0003-4819-156-4-201202210-00014

Editorial

Hepatitis C: the end of the beginning and possibly the beginning of the end

Harvey J Alter et al. Ann Intern Med. 2012.

. 2012 Feb 21;156(4):317-8.

doi: 10.7326/0003-4819-156-4-201202210-00014.

Authors

Harvey J Alter, T Jake Liang

PMID: 22351718
PMCID: PMC3480337
DOI: 10.7326/0003-4819-156-4-201202210-00014

No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0093.

Comment on

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. Rein DB, et al. Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4. Ann Intern Med. 2012. PMID: 22056542 Free PMC article.
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Liu S, et al. Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005. Ann Intern Med. 2012. PMID: 22351713 Free PMC article.

Similar articles

The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings.
Vuppalanchi R, Kwo PY. Vuppalanchi R, et al. Gastroenterology. 2013 Feb;144(2):457-459. doi: 10.1053/j.gastro.2012.12.013. Epub 2012 Dec 20. Gastroenterology. 2013. PMID: 23260498 No abstract available.
Clinical practice. Chronic hepatitis C infection.
Rosen HR. Rosen HR. N Engl J Med. 2011 Jun 23;364(25):2429-38. doi: 10.1056/NEJMcp1006613. N Engl J Med. 2011. PMID: 21696309 Review. No abstract available.
Antiviral agents and hepatitis C.
Archer-Festa M, Nilsen-Kupsch S. Archer-Festa M, et al. N Y State Dent J. 2012 Jun-Jul;78(4):42-5. N Y State Dent J. 2012. PMID: 23252194
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Liu S, et al. Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005. Ann Intern Med. 2012. PMID: 22351713 Free PMC article.
Protease inhibitors for hepatitis C: economic implications.
Turner SJ, Brown J, Paladino JA. Turner SJ, et al. Pharmacoeconomics. 2013 Sep;31(9):739-51. doi: 10.1007/s40273-013-0073-2. Pharmacoeconomics. 2013. PMID: 23839698 Review.

See all similar articles

Cited by

Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Cariani E, et al. Pharmacogenomics J. 2016 Feb;16(1):18-29. doi: 10.1038/tpj.2015.28. Epub 2015 Apr 28. Pharmacogenomics J. 2016. PMID: 25918016
Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.
Duan H, Kachko A, Zhong L, Struble E, Pandey S, Yan H, Harman C, Virata-Theimer ML, Deng L, Zhao Z, Major M, Feinstone S, Zhang P. Duan H, et al. J Virol. 2012 Dec;86(23):12686-94. doi: 10.1128/JVI.00994-12. Epub 2012 Sep 12. J Virol. 2012. PMID: 22973024 Free PMC article.
A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.
Zhao Z, Zhong L, Elrod E, Struble E, Ma L, Yan H, Harman C, Deng L, Virata-Theimer ML, Liu P, Alter H, Grakoui A, Zhang P. Zhao Z, et al. PLoS One. 2014 Jan 6;9(1):e84346. doi: 10.1371/journal.pone.0084346. eCollection 2014. PLoS One. 2014. PMID: 24400084 Free PMC article.
Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.
Liu S, Brandeau ML, Goldhaber-Fiebert JD. Liu S, et al. Health Care Manag Sci. 2017 Mar;20(1):16-32. doi: 10.1007/s10729-015-9330-6. Epub 2015 Jul 19. Health Care Manag Sci. 2017. PMID: 26188961 Free PMC article.
Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.
Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. Sheahan T, et al. Cell Host Microbe. 2014 Feb 12;15(2):190-202. doi: 10.1016/j.chom.2014.01.007. Cell Host Microbe. 2014. PMID: 24528865 Free PMC article.

See all "Cited by" articles

References

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. - PubMed
1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–500. - PubMed
1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–51. - PubMed
1. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206. - PMC - PubMed
1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov